Last updated on December 2019

Biomarkers of Irritant-Induced and Allergic Asthma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Asthma
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria for Phase I

For the WTC population with Irritant-Induced Asthma (IA):

  • > 18 years of age*
  • Current nonsmoker*
  • < 5 pack year (p-y) history of tobacco use*
  • Spirometry in the past 6 months or on day of evaluation with a bronchodilator response of 12% and 200 ml improvement in FEV
  • Positive methacholine challenge test (decrease in FEV1*

20% (PC20) after inhalation of < 16 mg/ml of methacholine)

  • Inhaled corticosteroid use in previous 1 month or more will be allowed*
  • Patients will be recruited from the WTC EHC and will have WTC dust cloud exposure
  • New symptoms after 9/11
  • Symptoms of wheeze and shortness of breath (> 2x / week) in the 4 weeks before inclusion (persistent symptoms).

Inclusion for Allergic Asthma Population (AA):

  • All of the above items with an asterisk (*)
  • Patients will be recruited from the NYUBAR or advertisement and will have asthma as defined by NIH guidelines, persistent symptoms, absence of WTC dust exposure.
  • Participants who will have completed the Phase I of the study and were able to produce adequate sputum samples.

Inclusion of Control Population:

  • Patients will be recruited from the NYUBAR and will have no respiratory symptoms, no asthma diagnosis, no WTC dust exposure, no current tobacco use, 5 p-y history of tobacco use, and normal spirometry with no bronchodilator response and negative methacholine challenge in past 6 months.

Inclusion Criteria for Phase II:

  • Successfully completed Phase I
  • Has asthma according to Phase I diagnostic criteria
  • Signed consent to be re-contacted

Exclusion Criteria:

  • Current Smoker
  • Pulmonary diseases such as Chronic Pulmonary Disease (COPD) or Interstitial Lung Disease
  • Cardiac Disease
  • Inability to perform lung function or other maneuvers
  • Upper respiratory tract infection within the last 4 weeks
  • FEV1 <60% predicted normal pre-bronchodilator
  • Oral corticosteroid treatment within the last 4 weeks.
  • No vulnerable subjects will be part of this study.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.